menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Squamous Cell Carcinoma of the Head and Neck (SCCHN): Focus on Recurrent/Metastatic Disease

close
Squamous Cell Carcinoma of the Head and Neck (SCCHN): Focus on Recurrent/Metastatic Disease
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Comments
  • Overview

    The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology and signal pathways. However, a significant proportion of patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck has a poor prognosis, in many cases due to late presentation. For those patients, cure is typically not possible; treatment options can prolong life and improve symptoms.  Thus, long-term survival rates in these metastatic settings, while improving, remain unacceptably low.

    Despite advances, the management of patients with metastatic disease continues to present challenges for clinicians. As innovative focused therapeutic options become available and treatment paradigms evolve, the need to discern when and how to incorporate these promising agents into clinicians’ armamentarium presents a great educational need. Moreover, continuing advances in our understanding of cancer pathophysiology, molecular pathways, the optimal and sequential use of targeted therapies in the context of chemotherapy and radiotherapy in the metastatic setting and the therapeutic potential of investigational agents currently being explored for various cancers, suggest educational and clinical practice gaps that must be effectively addressed to further improve outcomes in patients with cancer.

    Given this information, Siyemi Learning in partnership with Prova Education, presents this module titled “Squamous Cell Carcinoma of the Head and Neck (SCCHN): Focus on Recurrent/Metastatic Disease”. This module reviews the diagnosis and staging of SCCHN, the decision-making process in the selection of cytotoxic therapies, an assessment of current treatment modalities, overcoming resistance to platinum therapy and next-generation therapies for the treatment of recurrent/metastatic SCCHN.

  • Learning Objectives

    At the completion of this module, participants will be better able to:

    1. Describe appropriate steps in the diagnosis and staging of SCCHN
    2. Explain the decision-making process and factors in the selection of cytotoxic therapy for recurrent/metastatic SCCHN
    3. Assess the relative efficacy of treatment modalities for locoregional/locoregionally advanced SCCHN
    4. Evaluate the potential clinical applicability of next-generation therapies for the treatment of SCCHN
  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

    Original Release Date: 5 February 2015
    Expiration Date: 5 February 2017

  • Disclosure of Conflicts of Interest

    COURSE DIRECTOR

    Jan B. Vermorken, MD, PhD
    Emeritus Professor of Oncology
    Department of Medical Oncology 
    Antwerp University Hospital 
    Edegem, Belgium
    Financial Relationship Disclosure
    Consultant: Amgen, Genentech, Merck Serono, Shionogi      
    Commercial Interest Speakers Bureau: Merck Serono

    AUTHORS

    Joel Guigay, MD, PhD
    Director of Cancer Center
    Centre Antoine Lacassagne
    Nice, France
    Financial Relationship Disclosure
    Contracted Research: Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Serono

    Makoto Tahara, MD, PhD
    Department of Head and Neck Medical Oncology
    National Cancer Center Hospital East
    Chiba, Japan
    Financial Relationship Disclosure
    Consultant: Eisai, Merck Serono              
    Commercial Interest Speakers Bureau: Bristol-Myers Squibb, Merck Serono                       
    Contracted Research: Boehringer-Ingelheim, Eisai

    Jan B. Vermorken, MD, PhD
    Emeritus Professor of Oncology
    Department of Medical Oncology 
    Antwerp University Hospital 
    Edegem, Belgium
    Financial Relationship Disclosure
    Consultant: Amgen, Genentech, Merck Serono, Shionogi      
    Commercial Interest Speakers Bureau: Merck Serono

    REVIEWER

    Jennifer Grandis, MD, FACS
    Vice Chair for Research 
    Professor of Otolaryngology & Pharmacology 
    University of Pittsburgh School of Medicine 
    Program Leader, Head & Neck Cancer Program 
    University of Pittsburgh Cancer Institute 
    Pittsburgh, PA - USA
    Financial Relationship Disclosure
    Grant/Research Support: Bristol-Myers Squibb, Novartis

Facebook Comments

Recommended
Details
Comments
  • Overview

    The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology and signal pathways. However, a significant proportion of patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck has a poor prognosis, in many cases due to late presentation. For those patients, cure is typically not possible; treatment options can prolong life and improve symptoms.  Thus, long-term survival rates in these metastatic settings, while improving, remain unacceptably low.

    Despite advances, the management of patients with metastatic disease continues to present challenges for clinicians. As innovative focused therapeutic options become available and treatment paradigms evolve, the need to discern when and how to incorporate these promising agents into clinicians’ armamentarium presents a great educational need. Moreover, continuing advances in our understanding of cancer pathophysiology, molecular pathways, the optimal and sequential use of targeted therapies in the context of chemotherapy and radiotherapy in the metastatic setting and the therapeutic potential of investigational agents currently being explored for various cancers, suggest educational and clinical practice gaps that must be effectively addressed to further improve outcomes in patients with cancer.

    Given this information, Siyemi Learning in partnership with Prova Education, presents this module titled “Squamous Cell Carcinoma of the Head and Neck (SCCHN): Focus on Recurrent/Metastatic Disease”. This module reviews the diagnosis and staging of SCCHN, the decision-making process in the selection of cytotoxic therapies, an assessment of current treatment modalities, overcoming resistance to platinum therapy and next-generation therapies for the treatment of recurrent/metastatic SCCHN.

  • Learning Objectives

    At the completion of this module, participants will be better able to:

    1. Describe appropriate steps in the diagnosis and staging of SCCHN
    2. Explain the decision-making process and factors in the selection of cytotoxic therapy for recurrent/metastatic SCCHN
    3. Assess the relative efficacy of treatment modalities for locoregional/locoregionally advanced SCCHN
    4. Evaluate the potential clinical applicability of next-generation therapies for the treatment of SCCHN
  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

    Original Release Date: 5 February 2015
    Expiration Date: 5 February 2017

  • Disclosure of Conflicts of Interest

    COURSE DIRECTOR

    Jan B. Vermorken, MD, PhD
    Emeritus Professor of Oncology
    Department of Medical Oncology 
    Antwerp University Hospital 
    Edegem, Belgium
    Financial Relationship Disclosure
    Consultant: Amgen, Genentech, Merck Serono, Shionogi      
    Commercial Interest Speakers Bureau: Merck Serono

    AUTHORS

    Joel Guigay, MD, PhD
    Director of Cancer Center
    Centre Antoine Lacassagne
    Nice, France
    Financial Relationship Disclosure
    Contracted Research: Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Serono

    Makoto Tahara, MD, PhD
    Department of Head and Neck Medical Oncology
    National Cancer Center Hospital East
    Chiba, Japan
    Financial Relationship Disclosure
    Consultant: Eisai, Merck Serono              
    Commercial Interest Speakers Bureau: Bristol-Myers Squibb, Merck Serono                       
    Contracted Research: Boehringer-Ingelheim, Eisai

    Jan B. Vermorken, MD, PhD
    Emeritus Professor of Oncology
    Department of Medical Oncology 
    Antwerp University Hospital 
    Edegem, Belgium
    Financial Relationship Disclosure
    Consultant: Amgen, Genentech, Merck Serono, Shionogi      
    Commercial Interest Speakers Bureau: Merck Serono

    REVIEWER

    Jennifer Grandis, MD, FACS
    Vice Chair for Research 
    Professor of Otolaryngology & Pharmacology 
    University of Pittsburgh School of Medicine 
    Program Leader, Head & Neck Cancer Program 
    University of Pittsburgh Cancer Institute 
    Pittsburgh, PA - USA
    Financial Relationship Disclosure
    Grant/Research Support: Bristol-Myers Squibb, Novartis

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/2/21